Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
US9428508B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9428508-B2 |
| Application number | US-201213978475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 7, 2012 |
| Priority date | Jan 7, 2011 |
| Publication date | Aug 30, 2016 |
| Grant date | Aug 30, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from: or a pharmaceutically acceptable salt, solvate, or tautomer thereof. 2. A pharmaceutical composition comprising a) the compound of claim 1 or a pharmaceutically acceptable salt, solvate, or tautomer thereof, and b) a pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. 3. A method of treatment of a FAK and/or Pyk2 mediated disorder or disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 , wherein the disorder or disease is ovarian carcinoma or breast cancer.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunomodulators · CPC title
specific for metastasis · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9428508B2 cover?
- The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
- Who is the assignee on this patent?
- Xiao Dengming, Cheng Liang, Liu Xijie, and 14 more
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).